The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Invest New Drugs
; 39(3): 829-835, 2021 06.
Article
in En
| MEDLINE
| ID: mdl-33415580
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Antibodies, Monoclonal, Humanized
/
Immune Checkpoint Inhibitors
/
Granulosa Cell Tumor
/
Neoplasm Recurrence, Local
Type of study:
Guideline
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2021
Type:
Article
Affiliation country:
United States